ArticleMolecules (Basel, Switzerland)2019
Icariin Prevents Diabetes-Induced Bone Loss in Rats by Reducing Blood Glucose and Suppressing Bone Turnover.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- [Impact of icariin on the differentiation towards dentinogenesis and angiogenesis, and inflammatory regulation of stem cells from human exfoliated deciduous teeth].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Molecular mechanisms and preclinical evidence of natural products in diabetic osteoporosis: a review.Frontiers in endocrinology · 2026Review
- The Mechanism of Icariin in Regulating BMSCs for Treating Osteoporosis: A Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.Frontiers in pharmacology · 2026Review
- Research Progress on Icariin Promoting Bone Injury Repair and Regeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Icariin against osteoporosis: a review of advances in molecular mechanisms to biomedical applications.Frontiers in pharmacology · 2025Review
- Chemical composition and nutritional properties ofFrontiers in nutrition · 2025Article
- Ameliorative effect of Ononis natrix against chronic lead poisoning in mice: neurobehavioral, biochemical, and histological study.Biological trace element research · 2025Article
- Effects of whole-body vibration on bone properties in type 2 diabetes model rats.Osteoporosis and sarcopenia · 2024Article
- Review
- Icariin accelerates bone regeneration by inducing osteogenesis-angiogenesis coupling in rats with type 1 diabetes mellitus.World journal of diabetes · 2024Article
- Nanotherapy for bone repair: milk-derived small extracellular vesicles delivery of icariin.Drug delivery · 2023Article
- Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression.Biochemistry and biophysics reports · 2023Article
- Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.Molecules (Basel, Switzerland) · 2023Article
- Icariin synergizes therapeutic effect of dexamethasone on adriamycin-induced nephrotic syndrome.European journal of medical research · 2023Article
- Gut microbiome dysregulation drives bone damage in broiler tibial dyschondroplasia by disrupting glucose homeostasis.NPJ biofilms and microbiomes · 2023Article
- Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3×Tg-AD mice.Neural regeneration research · 2023Article
- Engineered 3D-Printed Polyvinyl Alcohol Scaffolds Incorporating β-Tricalcium Phosphate and Icariin Induce Bone Regeneration in Rat Skull Defect Model.Molecules (Basel, Switzerland) · 2022Article
- Icariin attenuates thioacetamide‑induced bone loss via the RANKL‑p38/ERK‑NFAT signaling pathway.Molecular medicine reports · 2022Article
- The Role of Flavonoids in the Osteogenic Differentiation of Mesenchymal Stem Cells.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Diabetic Osteoporosis (DOP) is a common metabolic bone disease, characterized by decreased bone mineral density (BMD) and destruction of bone microstructure. It has been reported that icariin is beneficial for estrogen deficiency-induced osteoporosis, and alcohol-induced osteoporosis; whether icariin has protective effects on diabetes-induced osteoporosis has not been reported. In this study, a rat model of diabetic osteoporosis was established by streptozotocin injection, the bone protective effects and potential mechanism of icariin on diabetes-induced bone loss was observed. Thirty 8-week-old female Sprague Dawley rats were divided into control group (vehicle treatment), T1DM (diabetic) group and T1DM-icariin (ICA) group (diabetic rats treated with icariin), 10 rats in each group. The bone histomorphometry parameters, bone mineral density (BMD), serum bone turnover markers, and bone marrow adipogenesis were analyzed after 8 weeks of icariin administration. The results showed consumption of icariin at a doses of 100 mg kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.